STAT June 13, 2024
On Thursday, the Supreme Court rejected an effort by anti-abortion doctors to bar the mailing of the abortion pill mifepristone. The case presented a serious challenge to the Food and Drug Administration’s authority to regulate medicines.
Biopharmaceutical companies and doctors organizations applauded the ruling but also warned that threats to mifepristone access are far from over.
Daphne Zohar, Seaport Therapeutics CEO:
“Today’s decision ensures patients and drug developers can rely on the rigorous FDA approval process as the scientific and trusted standard for drug approvals. Regulatory certainty is critical to ensuring that new medicines can make it from the lab bench to a patient’s bedside.”
Jim Stansel, general counsel of industry group PhRMA:
“We are pleased to see today’s...
Today's Sponsors
Today's Sponsor